DIECI, Maria Vittoria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.667
AS - Asia 2.958
EU - Europa 2.374
SA - Sud America 381
Continente sconosciuto - Info sul continente non disponibili 103
AF - Africa 78
OC - Oceania 7
Totale 11.568
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.521
SG - Singapore 807
CN - Cina 753
IT - Italia 583
GB - Regno Unito 452
HK - Hong Kong 386
IE - Irlanda 344
BR - Brasile 292
VN - Vietnam 292
BD - Bangladesh 234
SE - Svezia 219
DE - Germania 210
FI - Finlandia 136
KR - Corea 100
IN - India 98
RU - Federazione Russa 97
FR - Francia 91
CA - Canada 83
UA - Ucraina 73
ID - Indonesia 57
TR - Turchia 53
BG - Bulgaria 31
NL - Olanda 28
AR - Argentina 24
JP - Giappone 22
MX - Messico 22
ZA - Sudafrica 22
ES - Italia 21
CO - Colombia 20
IQ - Iraq 20
PL - Polonia 20
PK - Pakistan 16
TW - Taiwan 15
CR - Costa Rica 14
VE - Venezuela 12
CZ - Repubblica Ceca 11
MY - Malesia 11
AE - Emirati Arabi Uniti 10
CL - Cile 10
EC - Ecuador 10
EG - Egitto 10
SA - Arabia Saudita 10
TN - Tunisia 10
LT - Lituania 9
IR - Iran 8
PH - Filippine 8
AT - Austria 7
AU - Australia 7
BE - Belgio 7
DZ - Algeria 7
JM - Giamaica 7
JO - Giordania 6
KE - Kenya 6
MA - Marocco 6
PY - Paraguay 6
TH - Thailandia 6
UZ - Uzbekistan 6
AZ - Azerbaigian 5
RO - Romania 5
AL - Albania 4
DK - Danimarca 4
IL - Israele 4
LB - Libano 4
MD - Moldavia 4
NP - Nepal 4
OM - Oman 4
PT - Portogallo 4
TT - Trinidad e Tobago 4
BH - Bahrain 3
BO - Bolivia 3
DO - Repubblica Dominicana 3
EU - Europa 3
GR - Grecia 3
KZ - Kazakistan 3
PE - Perù 3
SC - Seychelles 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
CH - Svizzera 2
CI - Costa d'Avorio 2
HN - Honduras 2
LA - Repubblica Popolare Democratica del Laos 2
LY - Libia 2
MM - Myanmar 2
MT - Malta 2
NG - Nigeria 2
NI - Nicaragua 2
PR - Porto Rico 2
PS - Palestinian Territory 2
SN - Senegal 2
SY - Repubblica araba siriana 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AP - ???statistics.table.value.countryCode.AP??? 1
BF - Burkina Faso 1
BJ - Benin 1
BN - Brunei Darussalam 1
BZ - Belize 1
CY - Cipro 1
Totale 11.456
Salva come PNG Salva come JPEG
Città #
Ashburn 585
Santa Clara 549
Singapore 533
San Jose 393
Fairfield 391
Hong Kong 380
Dublin 344
Council Bluffs 255
Woodbridge 236
Southend 229
Chandler 219
Hefei 207
Houston 185
Seattle 177
Beijing 139
Ann Arbor 135
Cambridge 134
Dearborn 133
Wilmington 128
Los Angeles 123
Jacksonville 118
Chicago 116
Nyköping 113
London 111
The Dalles 100
Helsinki 92
Ho Chi Minh City 90
New York 87
Seoul 84
Hanoi 80
Milan 64
Dallas 61
Modena 49
Shanghai 47
Munich 46
Jakarta 45
Lauterbourg 43
Moscow 43
San Diego 43
Rome 42
Buffalo 38
Columbus 34
Princeton 34
São Paulo 32
Sofia 31
Boardman 28
Eugene 25
Tampa 25
Izmir 22
Naples 22
Phoenix 22
Salt Lake City 21
Elk Grove Village 20
Frankfurt am Main 20
Orem 20
Bologna 19
Falls Church 18
Mumbai 18
Toronto 18
Turin 18
Atlanta 16
Des Moines 16
Florence 16
Dong Ket 15
Guangzhou 15
Norwalk 15
Redwood City 15
Boston 14
Kent 14
Lappeenranta 14
Nuremberg 14
Ottawa 14
Tokyo 14
Chennai 13
Turku 13
Amsterdam 12
Bremen 12
Redondo Beach 12
Warsaw 12
Denver 11
Montreal 11
Taipei 11
Da Nang 10
Fremont 10
San José 10
Brooklyn 9
Catania 9
Dhaka 9
Haiphong 9
Johannesburg 9
Kunming 9
Lancaster 9
Miami 9
Padova 9
Sterling 9
Changsha 8
Genoa 8
Miano 8
Nanjing 8
Rio de Janeiro 8
Totale 7.893
Salva come PNG Salva come JPEG
Nome #
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 436
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 435
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 410
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 391
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 368
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 364
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 358
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 330
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 325
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 324
Immune characterization of breast cancer metastases: prognostic implications. 318
Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities 316
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 305
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 303
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 279
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 275
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 272
Preoperative carboplatin-paclitaxel-bevacizumab in triple negative breast cancer: Final results of the phase II CA.Pa.Be study 271
Timing for starting second-line therapy in recurrent ovarian cancer 249
Adding weekly carboplatin to sequential anthracycline and paclitaxel-based chemotherapy as neoadjuvant treatment for triple negative breast cancer (TNBC) patients: a propensity scorematched study 248
COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS 248
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2þ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. 246
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial 245
Tumori ginecologici 243
KI67 AS A PREDICTOR OF RESPONSE AND LONG TERM SURVIVAL IN HORMONE RECEPTOR POSITIVE/HER2 NEGATIVE BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 243
Pattern of distant relapse according to intrinsic molecular subtype in patients with HER2-positive breast cancer: a combined analysis of ShortHER, CherLOB, and two institutional cohorts 221
Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact 219
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial 215
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation 214
Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer 212
A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer 205
PIK3CA MUTATIONS IN HER2-POSITIVE BREAST CANCER PATIENTS ENROLLED IN THE ADJUVANT RANDOMIZED SHORT-HER STUDY. 200
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer 199
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer 187
Homologous recombination deficiency, RB-loss gene signatures, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2- early breast cancer: a correlative analysis of two phase II trials 186
MANAGEMENT OF ADVANCED BREAST CANCER: HOW TO INTEGRATE SCIENTIFIC DATA AND CLINICAL JUDGMENT 185
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2â € "Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial 158
Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation (British Journal of Cancer, (2023), 128, 2, (266-274), 10.1038/s41416-022-02050-8) 157
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer (BC). 143
Development of two machine learning models to predict conversion from primary HER2-0 breast cancer to HER2-low metastases: a proof-of-concept study 128
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study 125
Pregnancy after Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study 116
Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers 108
A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients. 99
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways 96
Interaction between tumor-infiltrating lymphocytes and BMI in early HER2-positive breast cancer: analysis of the ShortHER trial. 60
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer: 10-Year Analysis of the ShortHER Randomized Clinical Trial. 47
PREDICTIVE BRCA GENETIC TESTING IN ITALIAN PATIENTS WITH BREAST CANCER: A POSITION PAPER OF ITALIAN SCIENTIFIC SOCIETIES [Italian Association of Medical Oncology(AIOM); Italian Association of Radiotherapy and Clinical Oncology (AIRO); Italian National Association of Breast Surgeons (ANISC); Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP); Italian Society of Surgical Oncology (SICO); Italian Society of Human Genetic (SIGU); Italian Society of General Practice (SIMG); Italian Society of Medical and Interventional Radiology (SIRM)]. 42
The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives. 38
RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer 31
Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer 27
Prognosis and biological characteristics of ER-low metastatic breast cancer: results from a multicenter cohort and the TONIC trial. 26
Inclusion of platinum agents in neoadjuvant chemotherapy regimens for triple-negative breast cancer patients: Development of GRADE (grades of recommendation, assessment, development and evaluation) recommendation by the Italian association of medical oncology (AIOM) 26
PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology 26
Pregnancy after breast cancer in patients with germline BRCA mutations 22
Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology. 22
Basal-like HR + /HER2- breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implications. 20
Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study. 3
Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer. 3
Totale 11.568
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.893
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.893
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022528 0 0 77 19 25 35 32 33 66 60 120 61
2022/2023961 74 97 43 53 63 97 16 60 399 7 25 27
2023/2024572 24 24 30 27 77 39 69 118 25 23 39 77
2024/20251.888 54 27 30 139 360 313 138 103 182 107 188 247
2025/20264.361 271 142 305 425 630 248 534 219 374 429 394 390
2026/2027738 205 344 189 0 0 0 0 0 0 0 0 0
Totale 11.568